JP2020513804A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020513804A5 JP2020513804A5 JP2019549574A JP2019549574A JP2020513804A5 JP 2020513804 A5 JP2020513804 A5 JP 2020513804A5 JP 2019549574 A JP2019549574 A JP 2019549574A JP 2019549574 A JP2019549574 A JP 2019549574A JP 2020513804 A5 JP2020513804 A5 JP 2020513804A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- binding fragment
- tau
- pharmaceutical composition
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 7
- 102000036639 antigens Human genes 0.000 claims 7
- 108091007433 antigens Proteins 0.000 claims 7
- 239000012634 fragment Substances 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 230000004064 dysfunction Effects 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 238000004220 aggregation Methods 0.000 claims 2
- 230000002776 aggregation Effects 0.000 claims 2
- 230000001575 pathological effect Effects 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022164041A JP2022191383A (ja) | 2017-03-16 | 2022-10-12 | 抗ｐｈｆ－タウ抗体及びその使用 |
| JP2024055230A JP2024088689A (ja) | 2017-03-16 | 2024-03-29 | 抗ｐｈｆ－タウ抗体及びその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762472214P | 2017-03-16 | 2017-03-16 | |
| US62/472,214 | 2017-03-16 | ||
| PCT/US2018/022782 WO2018170351A1 (en) | 2017-03-16 | 2018-03-16 | Anti-phf-tau antibodies and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022164041A Division JP2022191383A (ja) | 2017-03-16 | 2022-10-12 | 抗ｐｈｆ－タウ抗体及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020513804A JP2020513804A (ja) | 2020-05-21 |
| JP2020513804A5 true JP2020513804A5 (https=) | 2021-04-15 |
| JP7159185B2 JP7159185B2 (ja) | 2022-10-24 |
Family
ID=63521020
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019549574A Active JP7159185B2 (ja) | 2017-03-16 | 2018-03-16 | 抗ｐｈｆ－タウ抗体及びその使用 |
| JP2022164041A Withdrawn JP2022191383A (ja) | 2017-03-16 | 2022-10-12 | 抗ｐｈｆ－タウ抗体及びその使用 |
| JP2024055230A Withdrawn JP2024088689A (ja) | 2017-03-16 | 2024-03-29 | 抗ｐｈｆ－タウ抗体及びその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022164041A Withdrawn JP2022191383A (ja) | 2017-03-16 | 2022-10-12 | 抗ｐｈｆ－タウ抗体及びその使用 |
| JP2024055230A Withdrawn JP2024088689A (ja) | 2017-03-16 | 2024-03-29 | 抗ｐｈｆ－タウ抗体及びその使用 |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US10766953B2 (https=) |
| EP (1) | EP3596119A4 (https=) |
| JP (3) | JP7159185B2 (https=) |
| KR (2) | KR102695287B1 (https=) |
| CN (2) | CN117209599A (https=) |
| AR (1) | AR111288A1 (https=) |
| AU (1) | AU2018234709B2 (https=) |
| CA (1) | CA3055598A1 (https=) |
| CL (1) | CL2019002566A1 (https=) |
| EA (1) | EA201992038A1 (https=) |
| IL (2) | IL268700B2 (https=) |
| JO (1) | JOP20180021A1 (https=) |
| MA (1) | MA47789A (https=) |
| MX (2) | MX2019010922A (https=) |
| MY (1) | MY205672A (https=) |
| PH (1) | PH12019501973A1 (https=) |
| SG (1) | SG11201907754RA (https=) |
| TW (1) | TWI771389B (https=) |
| UA (1) | UA128385C2 (https=) |
| UY (2) | UY37635A (https=) |
| WO (1) | WO2018170351A1 (https=) |
| ZA (2) | ZA202101318B (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX350311B (es) * | 2011-12-20 | 2017-09-01 | Janssen Biotech Inc | Anticuerpos anti-phf-tau y sus usos. |
| US10501531B2 (en) | 2013-03-13 | 2019-12-10 | Prothena Biosciences Limited | Tau immunotherapy |
| PT3452507T (pt) | 2016-05-02 | 2022-12-20 | Prothena Biosciences Ltd | Imunoterapia anti-tau |
| MY198194A (en) | 2016-05-02 | 2023-08-09 | Prothena Biosciences Ltd | Antibodies Recognizing Tau |
| SG11201907422RA (en) | 2017-02-17 | 2019-09-27 | Denali Therapeutics Inc | Anti-tau antibodies and methods of use thereof |
| KR102784294B1 (ko) | 2017-05-02 | 2025-03-19 | 프로테나 바이오사이언시즈 리미티드 | 타우 인식 항체 |
| AU2018352308B2 (en) | 2017-10-16 | 2025-06-05 | Eisai R&D Management Co., Ltd. | Anti-tau antibodies and uses thereof |
| CA3093200A1 (en) | 2018-03-05 | 2019-09-12 | Janssen Pharmaceutica Nv | Anti-phf-tau antibodies and uses thereof |
| JP7630834B2 (ja) | 2019-03-03 | 2025-02-18 | プロセナ バイオサイエンシーズ リミテッド | タウ認識抗体 |
| KR102905634B1 (ko) * | 2019-05-31 | 2025-12-30 | 일라이 릴리 앤드 캄파니 | 인간 타우를 표적화하는 화합물 및 방법 |
| JP7181438B2 (ja) * | 2019-08-06 | 2022-11-30 | アプリノイア セラピューティクス リミテッド | 病理学的タウ種に結合する抗体及びその使用 |
| US20230151083A1 (en) * | 2020-04-08 | 2023-05-18 | Janssen Biotech, Inc. | Anti-phf-tau antibodies and uses thereof |
| CN116348769A (zh) * | 2020-07-14 | 2023-06-27 | 詹森药业有限公司 | 用于检测tau蛋白病或淀粉样蛋白形成性疾病的基于血液的测定 |
| CA3199806A1 (en) * | 2020-10-26 | 2022-05-05 | Janssen Pharmaceutica Nv | Methods of reducing tau in human subjects |
| WO2022090169A1 (en) * | 2020-10-26 | 2022-05-05 | Janssen Pharmaceutica Nv | Method of safe administration of anti-tau antibody |
| MX2023008317A (es) * | 2021-02-19 | 2023-07-24 | Eisai R&D Man Co Ltd | Anticuerpo anti tau fosforilada en la treonina 217 (pt217). |
| EP4314048A1 (en) | 2021-03-26 | 2024-02-07 | Janssen Biotech, Inc. | Anti-tau antibodies and uses thereof |
| US20250034559A1 (en) | 2021-11-17 | 2025-01-30 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| CN117003863A (zh) * | 2022-04-28 | 2023-11-07 | 厦门大学 | 针对p-tau 217的抗体及其用途 |
| KR20250069606A (ko) | 2022-09-15 | 2025-05-19 | 보이저 테라퓨틱스, 인크. | 타우 결합 화합물 |
| CN116948023B (zh) * | 2023-09-14 | 2024-02-09 | 北京凯祥弘康生物科技有限公司 | Tau蛋白抗体及其应用 |
| CN116948024B (zh) * | 2023-09-14 | 2024-02-06 | 北京凯祥弘康生物科技有限公司 | 抗Tau蛋白的捕获抗体 |
| WO2025122634A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| DE69220503T2 (de) | 1991-10-25 | 1998-02-05 | Innogenetics Nv | Monoklonale Antikörper gegen das mikrotubulusassoziierte Protein Tau. |
| ES2270421T3 (es) * | 1993-12-21 | 2007-04-01 | Innogenetics N.V. | Anticuerpos monoclonales especificos para phf-tau, hibridomas que secretan los mismos, reconocimiento de antigeno por estos anticuerpos y sus aplicaciones. |
| WO1996004309A1 (en) | 1994-07-29 | 1996-02-15 | Innogenetics N.V. | Monoclonal antibodies specific for an epitope of a particular subclass or form of phosphorylated tau, hybridomas secreting them, antigen recognition of these antibodies and their applications |
| MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
| EP1590369B1 (en) * | 2003-01-24 | 2016-03-16 | Applied Molecular Evolution, Inc. | Human il-1 beta antagonists |
| AU2004297616B2 (en) | 2003-12-04 | 2008-12-18 | Xencor, Inc. | Methods of generating variant proteins with increased host string content and compositions thereof |
| EP1720908A2 (en) | 2004-02-17 | 2006-11-15 | Absalus, Inc. | Super-humanized antibodies against respiratory syncytial virus |
| US20070048785A1 (en) | 2004-06-09 | 2007-03-01 | Lin Laura L | Anti-IL-13 antibodies and complexes |
| EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| CA2659820A1 (en) | 2006-08-04 | 2008-02-14 | Novartis Ag | Ephb3-specific antibody and uses thereof |
| JP2010235447A (ja) | 2007-07-30 | 2010-10-21 | Igaku Seibutsugaku Kenkyusho:Kk | 炎症性サイトカインの抑制剤 |
| JP2012505654A (ja) | 2008-10-14 | 2012-03-08 | ヤンセン バイオテツク，インコーポレーテツド | 抗体をヒト化及び親和性成熟する方法 |
| CA2742969A1 (en) * | 2008-11-07 | 2010-05-14 | Fabrus Llc | Anti-dll4 antibodies and uses thereof |
| US9968574B2 (en) | 2009-05-15 | 2018-05-15 | The University Of Kentucky Research Foundation | Treatment of MCI and Alzheimer's disease |
| CN106390107B (zh) | 2009-06-10 | 2019-12-31 | 纽约大学 | 病理tau蛋白的免疫靶向 |
| US8609097B2 (en) | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
| US8912355B2 (en) | 2009-09-29 | 2014-12-16 | University Of Ottawa Heart Institute | Linoleic phospholipids and uses thereof for inhibiting inflammatory and neurodegenerative processes |
| JP2013508287A (ja) | 2009-10-14 | 2013-03-07 | ヤンセン バイオテツク，インコーポレーテツド | 抗体を親和性成熟する方法 |
| MX343227B (es) | 2010-04-09 | 2016-10-28 | Aveo Pharmaceuticals Inc | Anticuerpos anti-erbb3. |
| MY164376A (en) | 2010-10-07 | 2017-12-15 | Univ Leuven Kath | Phosphospecific antibodies recognizing tau |
| CA2813493C (en) * | 2010-10-11 | 2019-07-09 | University Of Zurich | Human anti-tau antibodies |
| MX350311B (es) * | 2011-12-20 | 2017-09-01 | Janssen Biotech Inc | Anticuerpos anti-phf-tau y sus usos. |
-
2018
- 2018-03-15 TW TW107108890A patent/TWI771389B/zh active
- 2018-03-16 US US15/923,011 patent/US10766953B2/en active Active
- 2018-03-16 EP EP18767083.1A patent/EP3596119A4/en active Pending
- 2018-03-16 MA MA047789A patent/MA47789A/fr unknown
- 2018-03-16 JP JP2019549574A patent/JP7159185B2/ja active Active
- 2018-03-16 AU AU2018234709A patent/AU2018234709B2/en active Active
- 2018-03-16 IL IL268700A patent/IL268700B2/en unknown
- 2018-03-16 KR KR1020237037321A patent/KR102695287B1/ko active Active
- 2018-03-16 CN CN202310854848.XA patent/CN117209599A/zh active Pending
- 2018-03-16 CN CN201880018431.7A patent/CN110799531B/zh active Active
- 2018-03-16 AR ARP180100620A patent/AR111288A1/es unknown
- 2018-03-16 CA CA3055598A patent/CA3055598A1/en active Pending
- 2018-03-16 MX MX2019010922A patent/MX2019010922A/es unknown
- 2018-03-16 MY MYPI2019005282A patent/MY205672A/en unknown
- 2018-03-16 KR KR1020197028728A patent/KR102597462B1/ko active Active
- 2018-03-16 WO PCT/US2018/022782 patent/WO2018170351A1/en not_active Ceased
- 2018-03-16 EA EA201992038A patent/EA201992038A1/ru unknown
- 2018-03-16 UY UY0001037635A patent/UY37635A/es not_active Application Discontinuation
- 2018-03-16 SG SG11201907754RA patent/SG11201907754RA/en unknown
- 2018-03-16 IL IL310464A patent/IL310464A/en unknown
- 2018-03-16 UA UAA201910307A patent/UA128385C2/uk unknown
- 2018-03-18 JO JOP/2018/0021A patent/JOP20180021A1/ar unknown
-
2019
- 2019-08-28 PH PH12019501973A patent/PH12019501973A1/en unknown
- 2019-09-09 CL CL2019002566A patent/CL2019002566A1/es unknown
- 2019-09-13 MX MX2024015440A patent/MX2024015440A/es unknown
-
2020
- 2020-08-06 US US16/986,615 patent/US11365244B2/en active Active
-
2021
- 2021-02-26 ZA ZA2021/01318A patent/ZA202101318B/en unknown
-
2022
- 2022-05-18 US US17/747,785 patent/US20230047413A1/en not_active Abandoned
- 2022-10-12 JP JP2022164041A patent/JP2022191383A/ja not_active Withdrawn
-
2023
- 2023-12-12 ZA ZA2023/11412A patent/ZA202311412B/en unknown
-
2024
- 2024-03-29 JP JP2024055230A patent/JP2024088689A/ja not_active Withdrawn
- 2024-07-19 UY UY0001040829A patent/UY40829A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020513804A5 (https=) | ||
| JP2018524001A5 (https=) | ||
| JP2019523753A5 (https=) | ||
| JP2019522490A5 (https=) | ||
| JP2022191383A5 (https=) | ||
| JP2015146822A5 (https=) | ||
| JP2020122013A5 (https=) | ||
| JP2016053091A5 (https=) | ||
| JP2020023523A5 (https=) | ||
| JP2010506596A5 (https=) | ||
| JP2019523221A5 (https=) | ||
| JP2019522961A5 (https=) | ||
| WO2017009308A3 (en) | Antibodies specific for hyperphosphorylated tau and methods of use thereof | |
| FI3461261T3 (fi) | Yksiketjuisen vaihtelevan fragmentin sisältäviä cd3:a sitovia proteiineja | |
| JP2018519810A5 (https=) | ||
| JP2016196468A5 (https=) | ||
| JP2019506841A5 (https=) | ||
| JP2017526350A5 (https=) | ||
| TN2018000419A1 (en) | Antibodies specific for hyperphosphorylated tau and methods of use thereof. | |
| JP2014506790A5 (https=) | ||
| FI3525583T3 (fi) | Anti-c1s-vasta-aineita ja niiden käyttömenetelmiä | |
| JP2015514423A5 (https=) | ||
| JP2018537399A5 (https=) | ||
| JP2017113019A5 (https=) | ||
| FI3390451T3 (fi) | Kaninisoidut ihmisen vasta-aineet ihmisen ja koiraeläimen il-4r alfaa kohtaan |